Supported by National Institute of Health
NIH support came as a R13 grant. Dr Franceschini is the PI of that grant and she is running the conference. Hence she has to disclose her conflict of interest.
Dr. Maria A. Franceschini has a financial interest in 149 Medical, Inc. This company is developing diffuse correlation spectroscopy (DCS) technology for assessing and monitoring cerebral blood flow (CBF) in newborn infants. Dr. Franceschini’s interests were reviewed and are managed by Mass General Hospital, and Mass General Brigham in accordance with their conflict of interest policies
for waiting list